D. Nalin

发表

Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers.

R. Chanock, B. Murphy, M. Rennels, 1980, Infection and immunity.

ESCHERICHIA COLI STRAINS THAT CAUSE DIARRHŒA BUT DO NOT PRODUCE HEAT-LABILE OR HEAT-STABLE ENTEROTOXINS AND ARE NON-INVASIVE

Daniel S Waterman, S. Sotman, D. Nalin, 1978, The Lancet.

CHOLERA, NON-VIBRIO CHOLERA, AND STOMACH ACID

D. Nalin, MyronM. Levine, R. Hornick, 1978, The Lancet.

Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality

D. Nalin, 1994, The Yale Journal of Biology and Medicine.

Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA.

D. Nalin, B. Mensch, B. Kuter, 2002, Vaccine.

The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults.

D. Nalin, W. Hurni, P. Reuman, 1997, Vaccine.

Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview.

B. Wiens, D. Nalin, E. Ellerbeck, 1993, Journal of hepatology.

Monthly Update: Anti-infectives: VAQTA: Merck's hepatitis A vaccine, purified, inactivated

D. Nalin, B. Kuter, W. Hurni, 1995 .

Six years' follow-up after hepatitis A vaccination.

D. Nalin, B. Kuter, A. Werzberger, 1998, The New England journal of medicine.

Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers.

D. Nalin, E. Ellerbeck, G. Calandra, 1991, The Journal of infectious diseases.

ORAL THERAPY WITH GLUCOSE ELECTROLYTE SOLUTION

D. Nalin, R. Black, M. Clements, 1980, The Lancet.

CHOLERA TRANSMISSION NEAR A CHOLERA HOSPITAL

D. Nalin, R. Levine, Stanislaus D'Souza, 1976, The Lancet.

The pathogenicity of nonenterotoxigenic Vibrio cholerae serogroup O1 biotype El Tor isolated from sewage water in Brazil.

L. Cisneros, D. Nalin, M. Levine, 1982, The Journal of infectious diseases.

Points: Diarrhoea, dehydration, and drugs

D. Nalin, 1985 .

Ex vivo antigen-pulsed PBMCs generate potent and long lasting immunity to infection when administered as a vaccine.

D. Nalin, E. Gosselin, R. Sunagar, 2017, Vaccine.

50 years of oral rehydration therapy: the solution is still simple

D. Nalin, R. Cash, 2018, The Lancet.

Oral maintenance therapy for cholera in adults.

D. Nalin, R. Phillips, R. Islam, 1968, Lancet.

Issues and Controversies in the Evolution of Oral Rehydration Therapy (ORT)

D. Nalin, 2021, Tropical medicine and infectious disease.

Effects of choleragenoid and glucose on the response of dog intestine to escherichia coli enterotoxins.

D. Nalin, J. Mclaughlin, J. McLaughlin, 1978, Journal of medical microbiology.

Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.

D. Nalin, C. Dinakar, M. Kumar, 1996, The Pediatric infectious disease journal.

Biohydrogenation of cholesterol as an index of bacterial 7α-dehydroxylase activity

D. Nalin, M. Levine, B. Nichols, 1981, Lipids.

Fever after immunization: current concepts and improved future scientific understanding.

D. Nalin, E. Rothstein, R. Dagan, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Rapid correction of acidosis and dehydration of cholera with oral electrolyte and glucose solution.

D. Nalin, E. Abrutyn, R. Cash, 1970, Lancet.

Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults.

D. Nalin, J. van Hattum, A. V. van Loon, 1997, Journal of hepatology.

Vaccines against hepatitis A and B

D. Nalin, M. Hilleman, J. Ryan, 1993 .

Fecal steroids in diarrhea: IV. Cholera

D. Nalin, M. Levine, B. Nichols, 1982, Lipids.

Recognition and treatment of anthrax.

D. Nalin, 1999, JAMA.

Adsorption and growth of Vibrio cholerae on chitin

L. Cisneros, D. Nalin, M. Levine, 1979, Infection and immunity.

CANNABIS, HYPOCHLORHYDRIA, AND CHOLERA

M. Rennels, D. Nalin, MyronM. Levine, 1978, The Lancet.

Cholera-like toxic effect of culture filtrates of Escherichia coli.

D. Nalin, A. Bhattacharjee, S. H. Richardson, 1974, The Journal of infectious diseases.

Increased Escherichia coli enterotoxin detection after concentrating culture supernatants: possible new enterotoxin detectable in dogs but not in infant mice

D. Nalin, M. Levine, E. Bergquist, 1978, Journal of clinical microbiology.

Inactivated hepatitis A vaccine in childhood: implications for disease control.

D. Nalin, K. Reisinger, M. Santosham, 1993, Vaccine.

Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity.

D. Nalin, M. Levine, D. Hoover, 1979, Transactions of the Royal Society of Tropical Medicine and Hygiene.

CHOLERA, COPEPODS, AND CHITINASE

D. Nalin, 1976, The Lancet.

CHLOPROMAZINE AND CHOLERA

D. Nalin, 1979, The Lancet.

Treatment of diarrhea.

D. Nalin, 1977, JAMA.

VILLAGE HEALTH EDUCATION AND ORAL DIARRHŒA THERAPY

D. Nalin, 1980, The Lancet.

Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin.

D. Nalin, J. Lewis, D. Shouval, 1993, Journal of hepatology.

Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A.

D. Nalin, E. Ellerbeck, J. Davide, 1992, Vaccine.

Use of norfloxacin to treat chronic typhoid carriers.

D. Nalin, E. Gotuzzo, C. Carrillo, 1988, The Journal of infectious diseases.

ORAL SUCROSE THERAPY FOR DIARRHŒA

D. Nalin, 1975, The Lancet.

Saliva and serum as diagnostic media for antibody to hepatitis A virus in adults and in individuals who have received an inactivated hepatitis A vaccine.

D. Nalin, W. Hurni, W. Miller, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The History of Intravenous and Oral Rehydration and Maintenance Therapy of Cholera and Non-Cholera Dehydrating Diarrheas: A Deconstruction of Translational Medicine: From Bench to Bedside?

D. Nalin, 2022, Tropical medicine and infectious disease.

Ivermectin for human strongyloidiasis and other intestinal helminths.

D. Nalin, C. Náquira, J. Guerra, 1989, The American journal of tropical medicine and hygiene.

Effect of glycine and glucose on sodium and water absorption in patients with cholera

M. Rahman, D. Nalin, R. Cash, 1970, Gut.

A clinical trial of oral therapy in a rural cholera-treatment center.

D. Nalin, L. Reller, R. Cash, 1970, The American journal of tropical medicine and hygiene.

Oral or nasogastric maintenance therapy for diarrhoea of unknown aetiology resembling cholera.

D. Nalin, R. Cash, 1970, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Comparison of low and high sodium and potassium content in oral rehydration solutions.

D. Nalin, M. Levine, D. Swaby, 1980, The Journal of pediatrics.

ORAL REHYDRATION OF NEONATES WITH DEHYDRATING DIARRHŒAS

D. Nalin, E. Mohs, L. Mata, 1979, The Lancet.

Evaluation of oral therapy for infant diarrhoea in an emergency room setting: the acute episode as an opportunity for instructing mothers in home treatment.

D. Nalin, M. Levine, E. Mohs, 1979, Bulletin of the World Health Organization.

Acetate in the correction of acidosis secondary to diarrhoea.

D. Nalin, R. Phillips, R. Cash, 1969, Lancet.

Antihelminthic Efficacy Against Trichuriasis.

D. Nalin, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

COMPARISON OF SUCROSE WITH GLUCOSE IN ORAL THERAPY OF INFANT DIARRHŒA

D. Nalin, MyronM. Levine, A. Simhon, 1978, The Lancet.

Immunity to Enterotoxigenic Escherichia coli

D. Nalin, M. Levine, D. Hoover, 1979, Infection and immunity.

CHOLERA RESEARCH IN BANGLADESH

D. Nalin, 1978, The Lancet.

CHOLERA RESEARCH IN BANGLADESH

D. Nalin, W. Mosley, J. Rohde, 1978, The Lancet.

Cholera or choleric?

D. Nalin, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Oral (or nasogastric) maintenance therapy for cholera patients in all age-groups.

M. Rahman, D. Nalin, R. Cash, 1970, Bulletin of the World Health Organization.

Comparison of low and high sodium content in oral rehydration solutions and potassium

D. Nalin, M. Levine, D. Swaby, 1980 .

Oral rehydration and maintenance of children with rotavirus and bacterial diarrhoeas.

D. Nalin, M. Levine, A. Simhon, 1979, Bulletin of the World Health Organization.

Oral or nasogastric maintenance therapy in pediatric cholera patients.

D. Nalin, R. Cash, 1971, The Journal of pediatrics.

Cholera and severe toxigenic diarrhoeas.

D. Nalin, 1994, Gut.

SUCROSE IN ORAL THERAPY FOR CHOLERA AND RELATED DIARRHŒAS

D. Nalin, 1975, The Lancet.

SODIUM CONTENT IN ORAL THERAPY FOR DIARRHŒA

D. Nalin, R. Cash, 1976, The Lancet.

Clinical concerns about reduced-osmolarity oral rehydration solution.

D. Nalin, G. Fuchs, W. Greenough, 2004, JAMA.

The problem of emesis during oral glucose-electrolytes therapy given from the onset of severe cholera.

M. Rennels, S. Sotman, D. Nalin, 1979, Transactions of the Royal Society of Tropical Medicine and Hygiene.

ORAL THERAPY FOR DIARRHŒA

D. Nalin, R. Cash, 1977, The Lancet.

SUCROSE OR GLUCOSE FOR DIARRHŒA

D. Nalin, N. Hirschhorn, 1977, The Lancet.

Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents

D. Nalin, R. Gilman, B. Weissberger, 1987, Antimicrobial Agents and Chemotherapy.

Oral rehydration solution.

D. Nalin, 1982, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Solutions for oral rehydration.

D. Nalin, 1987, The Journal of pediatrics.

ASPIRIN AND FLUID LOSSES IN DIARRHŒA

D. Nalin, M. Gracey, V. Burke, 1980, The Lancet.

Mortality from cholera and other diarrhoeal diseases at a cholera hospital.

D. Nalin, 1972, Tropical and geographical medicine.

CHOICE Study Group Trial

D. Nalin, R. Cash, N. Hirschhorn, 2002, Pediatrics.

Oral therapy for dehydration in acute diarrhoeal diseases with special reference to the global Diarrhoeal Diseases Control Programme.

D. Nalin, D. Mahalanabis, L. Finberg, 1979 .

Cholera and Pancreatic Cholera: Is VIP the Common Pathophysiologic Factor?

D. Nalin, T. Ahmed, F. Islam, 2020, Tropical medicine and infectious disease.

Oral Therapy for Cholera

D. Nalin, R. Cash, 1970 .

Comparison of oral rehydration solutions.

D. Nalin, 1989, Journal of pediatric gastroenterology and nutrition.

Colonization of Ascaris lumbricoides by V. cholerae.

D. Nalin, J. McLaughlin, 1976, The Journal of parasitology.

ENTEROTOXIGENIC ESCHERICHIA COLI AND IDIOPATHIC DIARRHŒA IN BANGLADESH

D. Nalin, M. Yunus, J. Mclaughlin, 1975, The Lancet.

Effect of cholera toxin on jejunal osmoregulation of mannitol solutions in dogs.

D. Nalin, K. Hare, K. Ally, 1972, The Journal of infectious diseases.

RICE POWDER AND ELECTROLYTE SOLUTIONS

D. Nalin, R. Cash, 1982, The Lancet.

Effect on clinical outcome of breast feeding during acute diarrhoea.

D. Nalin, 1985, British medical journal.

Oral or nasogastric therapy for cholera.

D. Nalin, R. Cash, 1970, Public health papers.

Oral therapy for cholera: amino acids added to electrolyte solutions containing rice or glucose.

D. Nalin, R. Cash, 2006, The Journal of infectious diseases.

HOUR OF ONSET OF CHOLERA AND DIARRHŒA

D. Nalin, MyronM. Levine, 1979, The Lancet.

A SPOONFUL OF SUGAR ...

D. Nalin, 1978, The Lancet.

Duration of infection-derived immunity to cholera.

L. Cisneros, D. Nalin, M. Levine, 1981, The Journal of infectious diseases.

Measles vaccine immunogenicity and antibody persistence in 12 vs 15-month old infants.

D. Nalin, M. Cleves, L. Chui, 2000, Vaccine.

Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin.

D. Nalin, S. Lemon, J. Davide, 1997, The Journal of infectious diseases.

Measles vaccine immunogenicity in 6- versus 15-month-old infants born to mothers in the measles vaccine era.

D. Nalin, L. Chui, M. Kumar, 1994, Pediatrics.

Mumps, measles, and rubella vaccination and encephalitis.

D. Nalin, 1989, BMJ.

Zinc and cholera.

D. Nalin, 2005, The Journal of infectious diseases.

Zinc and Cholera Reply to Nalin

D. Nalin, R. B. Canani, W. Chester, 2022 .

Imipenem/cilastatin therapy for serious infections in neonates and infants.

D. Nalin, C. Jacobsen, 1987, Scandinavian journal of infectious diseases. Supplementum.

Genetic susceptibility to cholera.

M. Rennels, S. Sotman, D. Nalin, 1979, Annals of human biology.

Solid-Phase Microtiter Radioimmunoassay Blocking Test for Detection of Antibodies to Escherichia coli Heat-Labile Enterotoxin

R. Chanock, D. Nalin, M. Levine, 1979, Journal of clinical microbiology.

Enterotoxigenic Escherichia coli and idiopathic diarrhoea in Bangladesh.

D. Nalin, M. Yunus, J. Mclaughlin, 1975, Lancet.

Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults.

B. Wiens, D. Nalin, E. Walter, 1999, Vaccine.

Control of hepatitis A through routine vaccination of children.

H. Margolis, E. Simard, D. Nalin, 2001, JAMA.

Sensitive assays for hepatitis a antibodies

D. Nalin, B. Kuter, W. Hurni, 1993, Journal of medical virology.

Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225.

D. Nalin, S. Chandwani, J. Moye, 2011, The Journal of infectious diseases.

FAILURE OF SANITARY WELLS TO PROTECT AGAINST CHOLERA AND OTHER DIARRHŒAS IN BANGLADESH

D. Nalin, R. Levine, RichardJ. Levine, 1976, The Lancet.

Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation.

Ron Dagan, Edward Rothstein, Lucia H. Lee, 2004, Vaccine.

Survival of a patient with intestinal anthrax.

D. Nalin, W. Greenough, M. A. Rahim, 1977, The American journal of medicine.

Duration of protection from clinical hepatitis A disease after vaccination with VAQTA®

B. Wiens, D. Nalin, J. Pigeon, 1996, Journal of medical virology.

Evaluating mumps vaccines

D. Nalin, 1992, The Lancet.

Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies.

Robert T. Chen, D. Nalin, M. Gold, 2009, Vaccine.

Temperature-sensitive mutants of influenza A virus: Evaluation of the Alaska/77-ts-1 A 2 temperature-sensitive recombinant virus in seronegative adult volunteers

R. Chanock, B. Murphy, R. Douglas, 2005, Archives of Virology.

Formulation of oral rehydration solution

D. Nalin, W. Greenough, R. Cash, 2002, The Lancet.

Oral replacement of water and electrolyte losses due to travellers' diarrhoea.

D. Nalin, 1983, Scandinavian journal of gastroenterology. Supplement.

Oral rehydration therapy

D. Nalin, 2009 .

Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers.

D. Nalin, L. Chui, M. Kumar, 1998, Vaccine.

Cholera Toxoid Boosts Serum Escherichia coli Antitoxin in Humans

D. Nalin, J. Peterson, G. Curlin, 1974, Infection and Immunity.

Diarrhea resembling cholera induced by Escherichia coli culture filtrate.

D. Nalin, S. H. Richardson, 1973, Lancet.

Template protocol for clinical trials investigating vaccines--focus on safety elements.

Robert T. Chen, S. Kochhar, D. Nalin, 2013, Vaccine.

Live Victoria/75-ts-1[E] Influenza A Virus Vaccines in Adult Volunteers: Role of Hemagglutinin Immunity in Protection Against Illness and Infection Caused by Influenza A Virus

R. Chanock, F. Hayden, R. Douglas, 1979, Infection and immunity.

Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus vaccine in Navajo children.

D. Nalin, L. Moulton, W. Newcomer, 1994, The Pediatric infectious disease journal.

INTRALUMINAL BINDING OF CHOLERA TOXIN

D. Nalin, 1981, The Lancet.

Failure of oral glucose therapy in short-bowel syndrome.

D. Nalin, 1972, Lancet.

Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems.

Robert T. Chen, D. Nalin, M. Gold, 2009, Vaccine.

Diarrhoea resembling cholera induced by Escherichia coli culture filtrate.

D. Nalin, A. Bhattacharjee, S. H. Richardson, 1973, The Lancet.

Recent advances in cholera pathophysiology and therapeutics.

D. Nalin, 1975, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

Evidence based vaccinology.

D. Nalin, David R Nalin, 2002, Vaccine.

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children.

B. Wiens, D. Nalin, R. Sitrin, 1992, The New England journal of medicine.

A simple antigen-reduction assay for the measurement of neutralizing antibodies to hepatitis A virus.

D. Nalin, P. Provost, D. Krah, 1991, The Journal of infectious diseases.

Anatomy of a trial: a historical view of the Monroe inactivated hepatitis A protective efficacy trial.

B. Wiens, D. Nalin, R. Sitrin, 1993, Journal of hepatology.

Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis.

D. Nalin, J. Davide, J. Lewis, 1993, Vaccine.

MUMPS VACCINE COMPLICATIONS: WHICH STRAIN?

D. Nalin, 1989, The Lancet.

Lack of person-to-person transmission of enterotoxigenic Escherichia coli despite close contact.

M. Rennels, L. Cisneros, D. Nalin, 1980, American journal of epidemiology.

CHOLERA IS PRIMARILY WATERBORNE IN BANGLADESH

D. Nalin, R. Levine, 1976, The Lancet.

Ebola and Cholera

D. Nalin, N. Hirschhorn, 2015, The American journal of tropical medicine and hygiene.

Hepatitis infections in the day-care setting.

D. Nalin, J. Hayashi, C. Deseda, 1994, Pediatrics.

Comment on: unexpected antimicrobial effect of statins.

D. Nalin, 2008, The Journal of antimicrobial chemotherapy.

Single-Dose Vaccines.

D. Nalin, 2015, The Journal of infectious diseases.